Drug intelligence / Profile preview

mesaconitine

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

Mesaconitine is a highly potent C19-diterpenoid alkaloid primarily derived from plants of the *Aconitum* genus, such as *Aconitum carmichaelii* (Fuzi). It is recognized as one of the major active and toxic constituents of these plants, which are traditionally used in East Asian medicine for the treatment of rheumatoid arthritis, joint pain, and inflammation. Mesaconitine exerts its biological effects by acting as a potent activator of voltage-gated sodium channels; it binds to site 2 of the channel's alpha subunit, preventing inactivation and leading to persistent membrane depolarization. This mechanism accounts for its analgesic properties as well as its severe cardiotoxicity and neurotoxicity. The compound is primarily metabolized by the cytochrome P450 enzyme CYP3A4 and is a substrate for the efflux transporter P-glycoprotein (P-gp). Its pharmacokinetics can be significantly altered by inflammatory conditions, such as rheumatoid arthritis, which may suppress the expression and function of these metabolic and transport pathways.

Other names
MA
02

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on mesaconitine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mesaconitine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call